教育背景
PhD candidate, University of Miami, 2026
实验室信息
The for Human Immunology, Autoimmunity, and Inflammation (CHI) within the National Institute of Allergy and Infectious Diseases (NIAID) aims to achieve an integrated and predictive understanding of human immunity and its behavior/function in health and disease. This goal is pursued through conducting large-scale human studies to investigate human immune responses in various health and disease states. The lab brings together a wide array of scientific knowledge and specialized skills tailored to novel technology and their application. This includes, leveraging cutting-edge technologies including genomics and proteomics, microscopy, spectral flow cytometry, CyTOF, and bioinformatics and/or computational biology for data analysis to the intramural community. Further, the lab translates new technology applications to identify and adapt biotechnological advancements for biomedical research, partners with investigators to create tailored technological solutions to address specific research questions, and develops new methods and approaches to advance immunological research.
https://www.niaid.nih.gov/research/nih-center-human-immunology-inflammation-and-autoimmunity-chi
研究方向
CyTOF, phospho-CyTOF, flow cytometry, monogenic disorders, immune cell signaling, JAK/STAT signaling, STAT1 hypomorphs, Immuno-oncology, CAR-T, CAR-M, Systems Immunology
发表论文
Waite, Janelle C., et al. “Tumor-Targeted CD28 Bispecific Antibodies Enhance the Antitumor Efficacy of PD-1 Immunotherapy.” Science Translational Medicine, vol. 12, no. 549, June 2020, p. eaba2325, https://doi.org/10.1126/scitranslmed.aba2325.
Skokos, Dimitris, et al. “A Class of Costimulatory CD28-Bispecific Antibodies That Enhance the Antitumor Activity of CD3-Bispecific Antibodies.” Science Translational Medicine, vol. 12, no. 525, Jan. 2020, p. eaaw7888, https://doi.org/10.1126/scitranslmed.aaw7888.
Wang, Bei, et al. “Combination Cancer Immunotherapy Targeting PD-1 and GITR Can Rescue CD8+ T Cell Dysfunction and Maintain Memory Phenotype.” Science Immunology, vol. 3, no. 29, Nov. 2018, p. eaat7061, https://doi.org/10.1126/sciimmunol.aat7061.
Papaspyridonos, Marianna, et al. “Id1 Suppresses Anti-Tumour Immune Responses and Promotes Tumour Progression by Impairing Myeloid Cell Maturation.” Nature Communications, vol. 6, no. 1, Apr. 2015, p. 6840, https://doi.org/10.1038/ncomms7840.
Chandra, Dinesh, et al. “STING Ligand C-Di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer.” Cancer Immunology Research, vol. 2, no. 9, Sept. 2014, pp. 901–10, https://doi.org/10.1158/2326-6066.CIR-13-0123.
Singh, Manisha, et al. “Curcumin Improves the Therapeutic Efficacy of Listeria ‐ Mage‐b Vaccine in Correlation with Improved T ‐cell Responses in Blood of a Triple‐negative Breast Cancer Model 4T1.” Cancer Medicine, vol. 2, no. 4, 2013, pp. 571–82, https://doi.org/10.1002/cam4.94.
Abstracts
Thomas, Dean E., et al. “Abstract 4585: Exploiting Intrinsic Bioelectrical Signatures for Label-Free Immune Cell Sorting.” Cancer Research, vol. 85, no. 8_Supplement_1, Apr. 2025, pp. 4585–4585, https://doi.org/10.1158/1538-7445.AM2025-4585.
Pierini, Stefano, et al. “Abstract 2112: Chimeric Antigen Receptor Macrophages (CAR-M) Sensitize Solid Tumors to Anti-PD1 Immunotherapy.” Cancer Research, vol. 82, no. 12_Supplement, June 2022, pp. 2112–2112, https://doi.org/10.1158/1538-7445.AM2022-2112.
Pierini, Stefano, et al. “139 Chimeric Antigen Receptor Macrophages (CAR-M) Elicit a Systemic Anti-Tumor Immune Response and Synergize with PD1 Blockade in Immunocompetent Mouse Models of HER2+ Solid Tumors.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021, pp. A148–A148, https://doi.org/10.1136/jitc-2021-SITC2021.139.